Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
Background: Switch maintenance is an effective strategy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor (TKI). EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum-based c...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 2015
|
| In: |
European journal of cancer
Year: 2015, Jahrgang: 51, Heft: 12, Pages: 1511-1528 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2015.04.026 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.ejca.2015.04.026 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804915003883 
|
| Verfasserangaben: | Mary E.R. O’Brien, Rabab Gaafar, Baktiar Hasan, Jessica Menis, Tanja Cufer, Sanjay Popat, Penella J. Woll, Veerle Surmont, Vassilis Georgoulias, Ana Montes, Fiona Blackhall, Ivo Hennig, Gerald Schmid-Bindert, Paul Baas, on behalf of the EORTC-LCG |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1585059358 | ||
| 003 | DE-627 | ||
| 005 | 20230427161342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181211s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2015.04.026 |2 doi | |
| 035 | |a (DE-627)1585059358 | ||
| 035 | |a (DE-576)515059358 | ||
| 035 | |a (DE-599)BSZ515059358 | ||
| 035 | |a (OCoLC)1341026910 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a O'Brien, Mary |e VerfasserIn |0 (DE-588)1144909392 |0 (DE-627)1005038929 |0 (DE-576)495511471 |4 aut | |
| 245 | 1 | 0 | |a Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy |b a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064) |c Mary E.R. O’Brien, Rabab Gaafar, Baktiar Hasan, Jessica Menis, Tanja Cufer, Sanjay Popat, Penella J. Woll, Veerle Surmont, Vassilis Georgoulias, Ana Montes, Fiona Blackhall, Ivo Hennig, Gerald Schmid-Bindert, Paul Baas, on behalf of the EORTC-LCG |
| 264 | 1 | |c August 2015 | |
| 300 | |a 18 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.12.2018 | ||
| 500 | |a Available online 11 June 2015 | ||
| 520 | |a Background: Switch maintenance is an effective strategy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor (TKI). EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum-based chemotherapy in patients with advanced NSCLC. Methods: Patients with non-progressive disease after 4-6 cycles of chemotherapy were randomised to receive either pazopanib 800mg/day or matched placebo until progression or unacceptable toxicity. The primary end-point was overall survival and secondary end-points were progression-free survival (PFS) and safety. Results: A total of 600 patients were planned to be randomised. The trial was prematurely stopped following an early interim analysis, after 102 patients were randomised to pazopanib (n=50) or placebo (n=52). Median age was 64years in both arms. Median overall survival was 17.4months for pazopanib and 12.3months for placebo (adjusted hazard ratio (HR) 0.72 [95% confidence interval (CI) 0.40-1.28]; p=0.257). Median PFS was 4.3months versus 3.2months (HR 0.67, [95% CI 0.43-1.03], p=0.068). PFS rates at 4months were 56% and 45% respectively. The majority of treatment-related adverse events (AEs) were grade 1-2. Grade 3-4 AEs (pazopanib versus placebo) were hypertension (38% versus 8%), neutropenia (8% versus 0%), and elevated SGPT (6% versus 0%). Of the patients randomised to pazopanib, 22% withdrew due to a treatment-related AE. Conclusions: Switch maintenance with pazopanib following platinum-based chemotherapy in advanced NSCLC patients had limited side-effects. This study was stopped due to lack of efficacy by stringent criteria for PFS at a futility interim analysis. | ||
| 650 | 4 | |a Advanced | |
| 650 | 4 | |a Double blind | |
| 650 | 4 | |a Maintenance | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a Pazopanib | |
| 650 | 4 | |a Phase III | |
| 700 | 1 | |a Schmid-Bindert, Gerald |d 1969- |e VerfasserIn |0 (DE-588)121300129 |0 (DE-627)081214170 |0 (DE-576)292636024 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 51(2015), 12, Seite 1511-1528 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064) |
| 773 | 1 | 8 | |g volume:51 |g year:2015 |g number:12 |g pages:1511-1528 |g extent:18 |a Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064) |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2015.04.026 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804915003883 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181211 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 121300129 |a Schmid-Bindert, Gerald |m 121300129:Schmid-Bindert, Gerald |d 60000 |e 60000PS121300129 |k 0/60000/ |p 13 | ||
| 999 | |a KXP-PPN1585059358 |e 3037374276 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Mary E.R. O’Brien, Rabab Gaafar, Baktiar Hasan, Jessica Menis, Tanja Cufer, Sanjay Popat, Penella J. Woll, Veerle Surmont, Vassilis Georgoulias, Ana Montes, Fiona Blackhall, Ivo Hennig, Gerald Schmid-Bindert, Paul Baas, on behalf of the EORTC-LCG"]},"id":{"doi":["10.1016/j.ejca.2015.04.026"],"eki":["1585059358"]},"relHost":[{"origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisher":"Elsevier ; Pergamon Press"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"recId":"266883400","disp":"Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)European journal of cancer","corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"display":"European Association for Cancer Research","role":"isb"},{"role":"isb","display":"European School of Oncology"}],"titleAlt":[{"title":"EJC online"}],"pubHistory":["28.1992 -"],"id":{"zdb":["1468190-0"],"issn":["1879-0852"],"eki":["266883400"]},"part":{"year":"2015","volume":"51","pages":"1511-1528","issue":"12","text":"51(2015), 12, Seite 1511-1528","extent":"18"}}],"person":[{"family":"O'Brien","given":"Mary","role":"aut","display":"O'Brien, Mary"},{"display":"Schmid-Bindert, Gerald","given":"Gerald","role":"aut","family":"Schmid-Bindert"}],"origin":[{"dateIssuedDisp":"August 2015","dateIssuedKey":"2015"}],"title":[{"title_sort":"Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy","title":"Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy","subtitle":"a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)"}],"note":["Gesehen am 11.12.2018","Available online 11 June 2015"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1585059358","physDesc":[{"extent":"18 S."}]} | ||
| SRT | |a OBRIENMARYMAINTENANC2015 | ||